Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMC information for gene therapy INDs addressed

This article was originally published in The Gold Sheet

Executive Summary

FDA issued a final guideline on April 9 specifying the type of CMC information to be included in investigational new drug applications (INDs) for gene therapy products. The guidance specifies the necessary sterility testing and microbiological testing to support INDs, and replaces a November 2004 draft. The guidance notes that "in order to deliver a safe and effective product, human gene therapies present many manufacturing challenges. Some of these challenges include the variability and complexity inherent in the components used to generate the final product, such as the source of cells, the potential for adventitious agent contamination, the need for aseptic processing, and in the case of ex vivo genetically modified cell therapies the inability to 'sterilize' the final product because it contains living cells.

You may also be interested in...



Gene Therapies: Safety, CMC Draft Guidances Coming From US FDA In 2018

Lengthy safety registries, extensive premarket testing for replication competent retrovirus, and manufacturing submission advice likely; pending CBER documents informed by review and approval of Novartis' Kymriah, Kite's Yescarta, and Spark's Luxturna.

New Data Position Lazertinib As Strong Contender In 1L NSCLC

Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.

Supreme Court Seems To Support Government’s Later Dismissal Of False Claims Act Case

Justices cite changing circumstances, constitutional concerns in preventing government from seeking dismissal of a case in which it initially declined to intervene. They also question whether government should intervene before moving to dismiss.

Latest News
See All
UsernamePublicRestriction

Register

PS000243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel